Q1 Earnings Estimate for Illumina Issued By Leerink Partnrs

Illumina, Inc. (NASDAQ:ILMN - Free Report) - Equities researchers at Leerink Partnrs lifted their Q1 2025 EPS estimates for Illumina in a note issued to investors on Tuesday, January 7th. Leerink Partnrs analyst P. Souda now forecasts that the life sciences company will post earnings per share of $0.85 for the quarter, up from their previous estimate of $0.84. The consensus estimate for Illumina's current full-year earnings is $4.11 per share.

A number of other brokerages have also recently issued reports on ILMN. Stephens upped their target price on Illumina from $170.00 to $184.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 12th. Barclays upped their price objective on shares of Illumina from $135.00 to $145.00 and gave the stock an "equal weight" rating in a report on Tuesday, November 5th. Hsbc Global Res upgraded shares of Illumina from a "hold" rating to a "strong-buy" rating and set a $180.00 target price on the stock in a research note on Thursday, October 17th. Citigroup lowered shares of Illumina from a "buy" rating to a "neutral" rating and cut their target price for the stock from $190.00 to $165.00 in a research report on Wednesday, December 11th. Finally, Morgan Stanley reaffirmed an "equal weight" rating and issued a $156.00 price target on shares of Illumina in a research report on Tuesday, November 12th. Eight analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $165.95.

Illumina Stock Up 0.4 %

Shares of ILMN traded up $0.60 during trading hours on Thursday, hitting $139.68. 1,342,769 shares of the company were exchanged, compared to its average volume of 1,406,074. The firm's 50 day moving average is $141.37 and its 200-day moving average is $132.08. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. Illumina has a 52 week low of $100.08 and a 52 week high of $156.66. The company has a market cap of $22.15 billion, a PE ratio of -14.02 and a beta of 1.11.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, topping the consensus estimate of $0.88 by $0.26. The company had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. Illumina's quarterly revenue was down 3.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.33 EPS.

Institutional Investors Weigh In On Illumina

Institutional investors and hedge funds have recently bought and sold shares of the business. Primecap Management Co. CA boosted its position in shares of Illumina by 462.5% during the 2nd quarter. Primecap Management Co. CA now owns 2,428,760 shares of the life sciences company's stock valued at $253,514,000 after acquiring an additional 1,997,010 shares in the last quarter. Millennium Management LLC boosted its holdings in Illumina by 305.0% during the second quarter. Millennium Management LLC now owns 1,485,599 shares of the life sciences company's stock valued at $155,067,000 after purchasing an additional 1,118,747 shares in the last quarter. Marshall Wace LLP acquired a new stake in Illumina during the second quarter valued at approximately $77,628,000. Massachusetts Financial Services Co. MA grew its stake in shares of Illumina by 148.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,056,172 shares of the life sciences company's stock valued at $137,735,000 after purchasing an additional 631,294 shares during the period. Finally, Janus Henderson Group PLC raised its holdings in shares of Illumina by 40.5% in the 3rd quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company's stock worth $282,735,000 after buying an additional 625,245 shares in the last quarter. Institutional investors own 89.42% of the company's stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.